Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Financing Activities (2018 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Cash from Financing Activities readings, the most recent being $6.1 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 119.4% to $6.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $36.3 million, a 218.08% increase, with the full-year FY2025 number at $33.0 million, up 169.22% from a year prior.
  • Cash from Financing Activities hit $6.1 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $7.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $11.9 million in Q3 2025 to a low of -$178000.0 in Q2 2024.
  • Median Cash from Financing Activities over the past 5 years was $1.2 million (2022), compared with a mean of $3.3 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 212.66% in 2024 and later soared 6110.11% in 2025.
  • Kiniksa Pharmaceuticals International's Cash from Financing Activities stood at $1.2 million in 2022, then crashed by 41.6% to $695000.0 in 2023, then surged by 208.2% to $2.1 million in 2024, then surged by 257.52% to $7.7 million in 2025, then decreased by 20.7% to $6.1 million in 2026.
  • The last three reported values for Cash from Financing Activities were $6.1 million (Q1 2026), $7.7 million (Q4 2025), and $11.9 million (Q3 2025) per Business Quant data.